American Society of Hematology

Figure 1

$Figure 1. Proapoptotic agent ABT737 causes PS exposure in platelets from a patient with Scott syndrome. Washed platelets from healthy control subjects or a patient with Scott syndrome were treated with ABT737 (10 μM) in the presence of 1 mM CaCl2. (A) Representative histograms (black lines) for AF647-annexin A5 binding after 1- or 3-h stimulation with ABT737. Markers M1, M2, and M3 indicate fractions of platelets with no, moderate, or high annexin A5 binding, respectively. Gray curves show unstimulated platelets treated with vehicle. (B) Corresponding dot plots (forward scatter vs AF647 fluorescence) of platelets treated with ABT737 or vehicle. (C) Distribution of M1, M2, and M3 platelet populations upon ABT737 treatment (10 μM).$

Proapoptotic agent ABT737 causes PS exposure in platelets from a patient with Scott syndrome. Washed platelets from healthy control subjects or a patient with Scott syndrome were treated with ABT737 (10 μM) in the presence of 1 mM CaCl₂. (A) Representative histograms (black lines) for AF647-annexin A5 binding after 1- or 3-h stimulation with ABT737. Markers M1, M2, and M3 indicate fractions of platelets with no, moderate, or high annexin A5 binding, respectively. Gray curves show unstimulated platelets treated with vehicle. (B) Corresponding dot plots (forward scatter vs AF647 fluorescence) of platelets treated with ABT737 or vehicle. (C) Distribution of M1, M2, and M3 platelet populations upon ABT737 treatment (10 μM).

This Feature Is Available To Subscribers Only